Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 3/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.51 |
| ▸ | DRD1 | P21728 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.51 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489815 | 0.93 | HTR1A (0.51) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL489547 | 0.93 | CACNA1C (0.44) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL489973 | 0.92 | HTR1A (0.52) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL489564 | 0.91 | TBXA2R (0.54) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL17999035 | 0.90 | HTR1A (0.39) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL489559 | 0.89 | CACNA1C (0.44) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL489534 | 0.88 | NR1I2 (0.47) | TBXA2RADRA1ASLC6A3KCNH2ABCB11 | |
| SCHEMBL489785 | 0.87 | CACNA1C (0.44) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL489555 | 0.86 | HTR1A (0.54) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL489514 | 0.85 | CACNA1C (0.52) | TBXA2RADRA1ASLC6A3HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470108-B1 | 1,4-DIHYDROPYRIDINE AND PYRIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENT RES FOUNDATION (IN) | 2016-08-24 | — | — | EP | claimed |
| EP-1542683-B1 | CALCIUM CHANNEL BLOCKERS | DIAKRON PHARMACEUTICALS INC (US) | 2013-01-09 | — | — | EP | claimed |
| US-8106062-B1 | Calcium channel blockers | DIAKRON PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | claimed |
| US-20090118334-A1 | METHOD OF TREATMENT OF CARDIAC AND/OR RENAL FAILURE USING A CALCIUM CHANNEL BLOCKER AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR OR AN ANGIOTENSIN II RECEPTOR BLOCKER | DIAKRON PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | US | claimed |
| US-20060058355-A1 | Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker | DITTRICH HOWARD C | 2006-03-16 | — | — | US | claimed |
| US-6852742-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2005-02-08 | — | — | US | claimed |
| US-20040006110-A1 | To modulate the activity of calcium channels, therapy of cardiovascular disease or neurological disorders, that are associated with calcium channels | Knobbe, Martens, Olson & Bear, LLP | 2004-01-08 | — | — | US | claimed |
| EP-1470108-B1 | 1,4-DIHYDROPYRIDINE AND PYRIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENT RES FOUNDATION (IN) | 2016-08-24 | — | — | EP | disclosed |
| EP-1542683-B1 | CALCIUM CHANNEL BLOCKERS | DIAKRON PHARMACEUTICALS INC (US) | 2013-01-09 | — | — | EP | disclosed |
| US-8106062-B1 | Calcium channel blockers | DIAKRON PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20090118334-A1 | METHOD OF TREATMENT OF CARDIAC AND/OR RENAL FAILURE USING A CALCIUM CHANNEL BLOCKER AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR OR AN ANGIOTENSIN II RECEPTOR BLOCKER | DIAKRON PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-7235570-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH (IN) | 2007-06-26 | — | — | US | disclosed |
| US-20060058355-A1 | Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker | DITTRICH HOWARD C | 2006-03-16 | — | — | US | disclosed |
| US-20050159455-A1 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH (IN) | 2005-07-21 | — | — | US | disclosed |
| US-6852742-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2005-02-08 | — | — | US | disclosed |
| US-20040006110-A1 | To modulate the activity of calcium channels, therapy of cardiovascular disease or neurological disorders, that are associated with calcium channels | Knobbe, Martens, Olson & Bear, LLP | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058355-A1 | Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker | ACE, AGTR2, REN | TBXA2R 50/4885ADRA1A 130/4885SLC6A3 1715/4885 |
| US-20090118334-A1 | METHOD OF TREATMENT OF CARDIAC AND/OR RENAL FAILURE USING A CALCIUM CHANNEL BLOCKER AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR OR AN ANGIOTENSIN II RECEPTOR BLOCKER | AGTR2, ACE, AGTR1 | TBXA2R 52/4885ADRA1A 125/4885SLC6A3 1786/4885 |
| US-20040006110-A1 | To modulate the activity of calcium channels, therapy of cardiovascular disease or neurological disorders, that are associated with calcium channels | RYR2, ORAI1, RYR1 | TBXA2R 537/4885ADRA1A 1307/4885SLC6A3 1607/4885 |
| US-20050159455-A1 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | RYR1, RYR2, ORAI1 | TBXA2R 1015/4885ADRA1A 1033/4885SLC6A3 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.